Exposing hormone-naïve prostate cancer cells to HRGs reduces aneuploidy and proliferation.[59] On the other hand, in androgen-independent prostate cancer, activation of HER2/HER3 increases androgen receptor transactivation and tumor growth.[60]. Here, ERBB2 is linked to prostate carcinoma.